March 3, 2014

AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

January 8, 2014

The Food and Drug Administration has approved a new drug made by Bristol-Myers Squibb and AstraZeneca for treating Type 2 diabetes, the agency said.

October 23, 2013

Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

September 10, 2013

Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.

July 15, 2013

Self-reported medication adherence rates increased among Type 2 diabetes patients using a mobile app, the maker of the app said Monday.

June 27, 2013

Target has ended its relationship with celebrity chef Paula Deen following reports that she used racial slurs, according to published reports.

April 19, 2013

The Food and Drug Administration has given tentative approval to two generic diabetes drugs made by Sun Pharmaceutical Industries, the Indian drug maker said.

March 22, 2013

A drug made by Novo Nordisk for Type 2 diabetes produced a 6% loss of weight in a trial of the drug in obese patients, the company said.

January 21, 2013

Drug maker GlaxoSmithKline is seeking Food and Drug Administration approval for a new treatment for Type 2 diabetes, the drug maker said.

August 9, 2012

AstraZeneca paid $3.2 billion to Amylin Pharmaceuticals Thursday following the latter's acquisition by Bristol-Myers Squibb, AstraZeneca and Bristol said.

August 8, 2012

Bristol-Myers Squibb has bought a majority stake in drug maker Amylin Pharmaceuticals, Bristol said Wednesday.

July 2, 2012

Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

June 14, 2012

A new Walgreens study released Thursday found that a pharmacist-led training and counseling program for patients receiving an injectable diabetes medication improved medication adherence by 24%.

June 12, 2012

One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.

June 11, 2012

When one of Amylin Pharmaceuticals' diabetes drugs is used with mealtime insulin, both Type 1 and Type 2 diabetes patients maintain blood sugar in the normal glucose range on a daily basis, according to two analyses presented at the 72nd Scientific Sessions of the American Diabetes Association.

June 11, 2012

An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.

May 22, 2012

Medical supply manufacturer BD has released a syringe with a shorter needle designed to reduce discomfort in patients with diabetes who must inject insulin, the company said Tuesday.

April 19, 2012

Generic drug maker Watson is challenging the patent protection on a drug used to treat Type 2 diabetes.

April 9, 2012

The Food and Drug Administration has approved a change to the label of a Novo Nordisk drug stating that it offers superior blood-sugar control to a competing drug made by Merck, based on results of two clinical studies, Novo Nordisk said Monday.

April 3, 2012

Drug maker Amylin Pharmaceuticals has filed for regulatory approval of a drug to treat diabetes and elevated triglycerides in the bloodstream in children and adults with a rare disorder.

April 2, 2012

A diabetes treatment made by Novo Nordisk is safe for pregnant women, according to a recent decision by the Food and Drug Administration.

April 2, 2012

A medication commonly prescribed for patients with Type 2 diabetes also may play a critical role in patients at risk of developing certain cancers.

March 29, 2012

A commonly prescribed diabetes drug also may have the capability of protecting the heart, according to a Swedish study.

March 26, 2012

Lifestyle intervention and treatment with metformin provide safe, long-term, cost-effective means of preventing Type 2 diabetes and should be incorporated into prevention strategies for reducing the dramatic rise in incidence of Type 2 diabetes in the United States, according to two new analyses and an editorial published in the April issue of Diabetes Care.